Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.